

Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)

Technology appraisal guidance

Published: 30 October 2019

www.nice.org.uk/guidance/ta609

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of ramucirumab for treating unresectable hepatocellular carcinoma in adults who have had sorafenib, when disease has progressed or sorafenib is not tolerated, because Lilly did not provide an evidence submission. The company has confirmed that it does not intend to make a submission for the appraisal because the technology is unlikely to be a cost-effective use of NHS resources.

Information

If NHS organisations wish to consider ramucirumab for treating unresectable hepatocellular carcinoma in adults who have had sorafenib, when disease has progressed or sorafenib is not tolerated, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-3571-0